Cargando…
The Quest for an Alzheimer Therapy
This mini-review considers three different approaches to the therapy and prevention of Alzheimer’s disease (AD): replacement therapy, disease modification, and multi-level interventions. Each of these research frameworks has direct implications at the clinical level, leading to an emphasis on differ...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863504/ https://www.ncbi.nlm.nih.gov/pubmed/29599741 http://dx.doi.org/10.3389/fneur.2018.00108 |
_version_ | 1783308404035420160 |
---|---|
author | Cappa, Stefano F. |
author_facet | Cappa, Stefano F. |
author_sort | Cappa, Stefano F. |
collection | PubMed |
description | This mini-review considers three different approaches to the therapy and prevention of Alzheimer’s disease (AD): replacement therapy, disease modification, and multi-level interventions. Each of these research frameworks has direct implications at the clinical level, leading to an emphasis on different time points of the AD continuum. While all perspectives continue to play an important role in current efforts to reach the ambitious target of an effective therapy or prevention of AD by 2025, it is clear that novel paradigms are needed, including new models of clinical trial design. This goal can only be accomplished by a concerted effort of academia, governmental agencies, and industry. |
format | Online Article Text |
id | pubmed-5863504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58635042018-03-29 The Quest for an Alzheimer Therapy Cappa, Stefano F. Front Neurol Neuroscience This mini-review considers three different approaches to the therapy and prevention of Alzheimer’s disease (AD): replacement therapy, disease modification, and multi-level interventions. Each of these research frameworks has direct implications at the clinical level, leading to an emphasis on different time points of the AD continuum. While all perspectives continue to play an important role in current efforts to reach the ambitious target of an effective therapy or prevention of AD by 2025, it is clear that novel paradigms are needed, including new models of clinical trial design. This goal can only be accomplished by a concerted effort of academia, governmental agencies, and industry. Frontiers Media S.A. 2018-03-01 /pmc/articles/PMC5863504/ /pubmed/29599741 http://dx.doi.org/10.3389/fneur.2018.00108 Text en Copyright © 2018 Cappa. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Cappa, Stefano F. The Quest for an Alzheimer Therapy |
title | The Quest for an Alzheimer Therapy |
title_full | The Quest for an Alzheimer Therapy |
title_fullStr | The Quest for an Alzheimer Therapy |
title_full_unstemmed | The Quest for an Alzheimer Therapy |
title_short | The Quest for an Alzheimer Therapy |
title_sort | quest for an alzheimer therapy |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863504/ https://www.ncbi.nlm.nih.gov/pubmed/29599741 http://dx.doi.org/10.3389/fneur.2018.00108 |
work_keys_str_mv | AT cappastefanof thequestforanalzheimertherapy AT cappastefanof questforanalzheimertherapy |